Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO 2023)

The oral, small molecule Wee1 kinase inhibitor adavosertib exerts antitumour effects in patients with advanced recurrent or persistent uterine serous carcinoma, but this benefit appears to be limited by the drug’s tolerability, as shown in the single-arm, phase IIb ADAGIO study.

The addition of pembrolizumab to standard chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, regardless of whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease, according to the NRG-GY018 trial presented at the SGO 2023.

Adding dostarlimab, an immune checkpoint inhibitor, to standard-of-care chemotherapy significantly improves progression-free survival (PFS) in patients with primary advanced or recurrent endometrial cancer, including those with dMMR-MSI-H* disease, according to the first interim analysis of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial presented at SGO 2023.

The use of gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy appears to improve response and prolong progression-free survival in women with locally advanced vulvar cancer not amenable to surgical resection, according to the results of the phase II NRG Oncology Trial 279 (NRG-GOG-0279) presented at SGO 2023.